The battle between U.K. authorities and Vertex Pharmaceuticals (VRTX) over the cost of its cystic fibrosis medicines took another twist as the drug maker declined to provide information about its newest treatment to a cost-effectiveness watchdog. In doing so, the company is delaying the approval process used to make the new treatment available to patients.
The move is the latest bit of brinkmanship between the drug maker and government officials, who have been haggling for more than two years. And the impasse underscores the rising friction that can occur when cash-strapped governments confront high-priced medicines, an issue that is engulfing a growing number of countries, prompting patients to complain they have become pawns.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
this is ridiculous. Orkambi is clearly a drug that prolongs life for people who respond to it, and improves quality of life as well. Both parties have culpability here. And patients are left dangling. Let’s get this done people!